Let’s look at the key reasons that are pushing Candel Therapeutics Inc (CADL) to new highs

On Monday, Candel Therapeutics Inc (NASDAQ: CADL) opened higher 7.44% from the last session, before settling in for the closing price of $8.06. Price fluctuations for CADL have ranged from $1.42 to $14.60 over the past 52 weeks.

During the last 5-year period, the sales drop of Healthcare Sector giant was -20.00%. Company’s average yearly earnings per share was noted 29.34% at the time writing. With a float of $34.58 million, this company’s outstanding shares have now reached $46.93 million.

Let’s determine the extent of company efficiency that accounts for 38 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Candel Therapeutics Inc (CADL) Breakdown of a Key Holders of the stock

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Candel Therapeutics Inc is 26.79%, while institutional ownership is 33.94%. The most recent insider transaction that took place on Mar 18 ’25, was worth 396,995. In this transaction Chief Medical Officer of this company sold 45,316 shares at a rate of $8.76, taking the stock ownership to the 52,493 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Scientific Officer sold 32,146 for $8.76, making the entire transaction worth $281,673. This insider now owns 96,527 shares in total.

Candel Therapeutics Inc (CADL) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 29.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.13% during the next five years compared to -43.86% drop over the previous five years of trading.

Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators

Check out the current performance indicators for Candel Therapeutics Inc (CADL). In the past quarter, the stock posted a quick ratio of 2.77.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.75, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -1.51 in one year’s time.

Technical Analysis of Candel Therapeutics Inc (CADL)

Looking closely at Candel Therapeutics Inc (NASDAQ: CADL), its last 5-days average volume was 1.21 million, which is a drop from its year-to-date volume of 1.23 million. As of the previous 9 days, the stock’s Stochastic %D was 46.58%. Additionally, its Average True Range was 0.75.

During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 45.08%, which indicates a significant decrease from 70.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.84% in the past 14 days, which was lower than the 160.95% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.24, while its 200-day Moving Average is $6.73. However, in the short run, Candel Therapeutics Inc’s stock first resistance to watch stands at $8.82. Second resistance stands at $8.97. The third major resistance level sits at $9.26. If the price goes on to break the first support level at $8.38, it is likely to go to the next support level at $8.09. Now, if the price goes above the second support level, the third support stands at $7.94.

Candel Therapeutics Inc (NASDAQ: CADL) Key Stats

There are currently 47,235K shares outstanding in the company with a market cap of 409.06 million. Presently, the company’s annual sales total 0 K according to its annual income of -55,180 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -14,070 K.